IBO stock forecast, quote, news & analysis
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases... Show more
Why Impact BioMedical (IBO) Stock Is Up +51% in the Last 30 Days
Key Takeaways
- IBO shares climbed roughly 51% over the trailing 30 days, from a closing price of $3.40 on October 14, 2026, to $5.14 on November 13, 2026.
- The rebound followed a steep October selloff and coincided with major milestones in the proposed business combination with Zoar Limited.
- The U.S. Securities and Exchange Commission declared Zoar's Form F-4 registration statement effective on October 23, 2026, paving the way for a November 13, 2026 stockholder vote.
- A 1-for-12.62 reverse stock split took effect on September 23, 2026, reducing shares outstanding from roughly 107.8 million to approximately 8.5 million.
- Despite the sharp 30-day recovery, shares remain modestly lower versus mid-August levels, reflecting the stock's pronounced volatility.
- IBO is a high-volatility micro-cap, with a beta near 2.9 and a 52-week trading range of $2.43 to $10.48.
- For additional context on valuation and fundamentals, explore dedicated Price Targets, Earnings, and Forecast pages for IBO.
- Discover curated, top-performing trading strategies on Trending AI Robots.
Impact BioMedical (IBO) Company Overview and Market Position
Impact BioMedical, Inc. is a life-sciences holding company that discovers, patents, and licenses proprietary technologies in human healthcare and wellness. Through subsidiaries such as Global BioLife, the company pursues applications across specialty biopharmaceuticals, antivirals, antimicrobials, and consumer wellness, generally advancing its science through research, licensing, co-development, and joint-venture partnerships rather than large-scale in-house commercialization. The company's majority shareholder is DSS, Inc. (DSS). Investor attention on IBO is driven largely by its proposed business combination with Zoar Limited, a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients (APIs), intermediates, and orphan drugs.
Impact BioMedical (IBO) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, IBO advanced from a closing price of $3.40 on October 14, 2026, to $5.14 on November 13, 2026 — a gain of approximately 51%. The move marked a sharp reversal after the stock bottomed near an intraday low of $2.43 in mid-October.
The longer three-month trend tells a different story. From a mid-August level of roughly $5.55, shares are down about 7% as of the November 13 close. During that span, IBO spiked to a peak near $7.45 in mid-September, then declined steeply through October before the recent recovery. This wide trading range underscores the stock's high-beta, event-driven character.
What Drove IBO Stock Price in the Last 30 Days
The 30-day advance was closely tied to progress on the Zoar Limited business combination. On October 23, 2026, the SEC declared Zoar's Form F-4 registration statement effective, a key regulatory milestone that allowed the definitive proxy materials to be mailed to stockholders. On November 2, 2026, Impact BioMedical announced that its special meeting of stockholders was scheduled for November 13, 2026, to vote on the merger. The company also published its third-quarter 2026 results in November.
The rebound was amplified by the stock's thin trading and elevated volatility. After the October selloff, any incremental positive development around the merger timeline produced outsized percentage moves. The approaching stockholder vote, combined with expectations that the combined entity would operate as a pharmaceutical company under the name Zoar Limited, helped support renewed buying interest in the shares.
What Drove IBO Stock Performance Over the Last Quarter
The broader quarterly trend was shaped by a sequence of corporate actions. In early-to-mid September, optimism around the proposed merger and a planned reverse stock split helped lift IBO toward its quarterly peak near $7.45. A 1-for-12.62 reverse stock split then became effective on September 23, 2026, cutting shares outstanding to roughly 8.5 million.
Post-split selling pressure drove a sharp decline through October, with the stock reaching an intraday low near $2.43 on October 16, 2026. The stock subsequently stabilized and recovered as merger milestones advanced — most notably the SEC's declaration of effectiveness of the Form F-4 on October 23, 2026 — restoring investor confidence and setting up the November rebound.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a platform that offers hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, helping traders filter a broad universe down to a focused set of strategies. The bots vary in approach, holding timeframe, and performance metrics, so investors can review different methods rather than a single standardized model. For those following volatile, event-driven names like IBO, the page offers a way to explore systematic strategies alongside traditional fundamental research.
IBO Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term variable is the outcome of the proposed Zoar business combination. Completion remains subject to stockholder approval, approval for the listing of the combined company's ordinary shares on NYSE American, and satisfaction of closing conditions, with an amended outside date of November 20, 2026. The proxy materials indicate that existing Impact stockholders would hold approximately 4.80% of the post-combination company, meaning the transaction is expected to be materially dilutive to current holders even as it brings Zoar's API and CDMO operations into the combined entity.
Investors should also monitor the combined company's post-closing fundamentals, its ability to secure NYSE American listing approval, and any further regulatory or financing conditions. Given the stock's elevated beta, low share count, and event-driven trading, price swings may remain pronounced regardless of the underlying fundamentals. These factors, along with future earnings disclosures and any changes to the merger terms, are central to the outlook for IBO.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IBO's RSI Indicator ascending out of oversold territory
The RSI Oscillator for IBO moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 9 similar instances when the indicator left oversold territory. In 8 of the 9 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on IBO as a result. In 31 of 41 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for IBO just turned positive on October 23, 2026. Looking at past instances where IBO's MACD turned positive, the stock continued to rise in 12 of 15 cases over the following month. The odds of a continued upward trend are 80%.
IBO moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBO advanced for three days, in 72 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 28 of 32 cases where IBO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
IBO broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. IBO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.254) is normal, around the industry mean (3.498). P/E Ratio (0.369) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology